2023
COVA clinical study: Results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients. Poster presented at European Respiratory Society 21st Lung Science Conference, 9–12 March 2023, Estoril, Portugal
COVA study: results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of BIO101 in hospitalized COVID-19 patients. Oral Presentation of Dr Girish Nair, MD at American Thoracic Society conference, 19-24 MAY 2023, Washington, USA
COVA clinical study: Results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients. Poster presented at American Thoracic Society conference, 19-24 MAY 2023, Washington, USA